Note 3 - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Loss Per Share (Details) - shares |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Antidilutive securities (in shares) | 4,556,229 | 4,462,805 |
| Convertible Debt Securities [Member] | ||
| Antidilutive securities (in shares) | 4,082,407 | 4,393,933 |
| Representative's Warrants [Member] | ||
| Antidilutive securities (in shares) | 62,500 | 62,500 |
| Share-Based Payment Arrangement, Option [Member] | ||
| Antidilutive securities (in shares) | 0 | 50 |
| BP Peptides Warrant [Member] | ||
| Antidilutive securities (in shares) | 6,322 | 6,322 |
| February 3i Warrants [Member] | ||
| Antidilutive securities (in shares) | 405,000 | 0 |